Ovarian Carcinoma Clinical Trials

37 recruiting

Ovarian Carcinoma Trials at a Glance

80 actively recruiting trials for ovarian carcinoma are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Phase 2 with 29 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running ovarian carcinoma studies include National Cancer Institute (NCI), Mayo Clinic, and M.D. Anderson Cancer Center.

Browse ovarian carcinoma trials by phase

Treatments under study

About Ovarian Carcinoma Clinical Trials

Looking for clinical trials for Ovarian Carcinoma? There are currently 37 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ovarian Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ovarian Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 80 trials

Recruiting
Phase 1

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Recurrent Endometrial CarcinomaRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Ovarian Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)65 enrolled14 locationsNCT05950464
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Not Applicable

The Vanguard Study: Testing a New Way to Screen for Cancer

Breast CarcinomaOvarian CarcinomaBladder Carcinoma+8 more
National Cancer Institute (NCI)24,000 enrolled37 locationsNCT06995898
Recruiting
Phase 2

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting

Prospective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma

Breast CarcinomaOvarian Carcinoma
Centre Leon Berard160 enrolled1 locationNCT04562623
Recruiting
Phase 1

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian Carcinoma
National Cancer Institute (NCI)42 enrolled27 locationsNCT04633239
Recruiting
Phase 1

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Ovarian CancerOvarian CarcinomaRecurrent Platinum-Resistant Ovarian Carcinoma+1 more
Elizabeth Stover, MD, PhD30 enrolled3 locationsNCT06964009
Recruiting
Phase 2

Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy

Ovarian CancerOvarian Cancer Metastatic RecurrentOvarian Cancer (OvCa)+1 more
Yonsei University116 enrolled1 locationNCT07340164
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Ovarian CancerOvarian CarcinomaAdvanced Solid Tumor+8 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Malignant Solid Neoplasm+7 more
University of Washington2,000 enrolled1 locationNCT06295965
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Non-small Cell Lung Cancer (NSCLC)High-grade Serous Ovarian Carcinoma (HGSOC)Uterine Serous Carcinoma (USC)
Bristol-Myers Squibb240 enrolled17 locationsNCT06476808
Recruiting
Phase 1

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

Breast CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma+5 more
M.D. Anderson Cancer Center300 enrolled1 locationNCT03604315
Recruiting
Phase 2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494
Recruiting
Not Applicable

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Carcinoma+4 more
Dana-Farber Cancer Institute240 enrolled6 locationsNCT06710548
Recruiting
Not Applicable

Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians

Ovarian CarcinomaPsychiatric Disorder
Fred Hutchinson Cancer Center25 enrolled1 locationNCT07282158
Recruiting
Phase 1

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Metastatic Endometrial CarcinomaStage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8+8 more
National Cancer Institute (NCI)42 enrolled6 locationsNCT05691504
Recruiting
Phase 3

A Study of Intra-operative Imaging in Women With Ovarian Cancer

Ovarian CancerOvarian Carcinoma
Memorial Sloan Kettering Cancer Center310 enrolled9 locationsNCT04878094
Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more
National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401
Recruiting
Phase 1Phase 2

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+13 more
Mayo Clinic40 enrolled3 locationsNCT05920798